Novartis Rolls Out Cosentyx 300 mg Pen in Japan

Novartis Pharma on November 30 launched a new 300 mg pen formulation of its psoriasis treatment Cosentyx (secukinumab) in Japan. The drug is already available in 75 mg syringe and 150 mg pen forms. Cosentyx, an anti-IL-17 antibody, is approved...read more